Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity

Citations Over Time

Abstract

Tetracyclic guanines have been shown to be potent and selective inhibitors of the cGMP-hydrolyzing enzymes PDE1 and PDE5. In general, these compounds are inactive or only weakly active as inhibitors of PDE3, which is a major isozyme involved in cAMP hydrolysis. Structure-activity relationships are developed at N-1, C-2, N-3, and N-5 on the core nucleus. Compound 31, with an IC50 of 70 pM, is the most potent inhibitor of PDE1, while 50, with an IC50 of 4 nM, is the most potent inhibitor of PDE5. Compounds 20, 22, 30, and 50 are potent dual inhibitors with IC50 values below 30 nM for both PDE1 and PDE5. Compounds 12, 20, and 28 reduced blood pressure by more than 45 mmHg when administered orally at 10 mg/kg to the spontaneously hypertensive rat (SHR).

Related Papers

• → Imaging of PDE2- and PDE3-Mediated cGMP-to-cAMP Cross-Talk in Cardiomyocytes(2018)32 cited
• → Inhibition by guanosine cyclic monophosphate (cGMP) analogues of uptake of [3H]3′,5′-cGMP without stimulation of ATPase activity in human erythrocyte inside-out vesicles11Abbreviations: 3′,5′-cGMP, guanosine 3′,5′-cyclic monophosphate; 2′,3′-cGMP, guanosine 2′,3′-cyclic monophosphate; N-mb-cGMP, N2-monobutyryl guanosine 3′,5′-cyclic monophosphate; O-mb-cGMP, 2′-O-monobutyryl guanosine 3′,5′-cyclic monophosphate; Db-cGMP, N2,2′-O-dibutyryl guanosine 3′,5′-cyclic monophosphate; Br-cGMP, 8′-bromo guanosine 3′,5′-cyclic monophosphate; Rp-cGMPS, Rp-monophosphorothioate guanosine 3′,5′-cyclic monophosphate; Sp-cGMPS, Sp-monophosphorothioate guanosine 3′,5′-cyclic monophosphate; 3′,5′-cAMP, Adenosine 3′,5′-cyclic monophosphate; and MRP, multidrug resistance protein.(2001)17 cited
• → A soluble interaction between dibutyryl cyclic guanosine 3′:5′-monophosphate and cholecystokinin: A possible mechanism for the inhibition of cholecystokinin activity(1983)18 cited
• → Guanylyl Cyclase, Particular(2007)
• Phosphodiesterase 3:new targets for drug development(2002)